Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mirum Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mirum Pharmaceuticals's regulatory disclosures and financial reporting.
Mirum Pharmaceuticals, Inc. (MIRM) – Form 4 insider transaction filing. SVP & Global Controller Jolanda Howe reported three transactions between 1–3 July 2025.
- 1 Jul 2025: 1,041 restricted stock units (RSUs) converted into an equal number of common shares (Transaction Code M). Post-conversion ownership temporarily rose to 3,467 shares.
- 2 Jul 2025: 564 shares sold at $48.25 (Code S) to cover tax-withholding obligations tied to the RSU vesting.
- 3 Jul 2025: 477 shares sold at $49.08 under a pre-existing Rule 10b5-1 plan adopted 16 Dec 2024.
Following these actions, Howe’s direct beneficial ownership declined from 3,467 to 2,426 common shares. All 1,041 RSUs from the reported award are now fully settled, leaving no outstanding derivative securities.
The RSU grant vests in three equal annual installments that began on 1 Jul 2023. All reported transactions were executed by a single insider; no joint filings were made.